Myostatin as a biomarker of muscle wasting and other pathologies-state of the art and knowledge gaps

J Baczek, M Silkiewicz, ZB Wojszel - Nutrients, 2020 - mdpi.com
Sarcopenia is a geriatric syndrome with a significant impact on older patients' quality of life,
morbidity and mortality. Despite the new available criteria, its early diagnosis remains …

Common pathogenic mechanisms in centronuclear and myotubular myopathies and latest treatment advances

R Gómez-Oca, BS Cowling, J Laporte - International journal of molecular …, 2021 - mdpi.com
Centronuclear myopathies (CNM) are rare congenital disorders characterized by muscle
weakness and structural defects including fiber hypotrophy and organelle mispositioning …

Therapeutic approaches in different congenital myopathies

C Gineste, J Laporte - Current Opinion in Pharmacology, 2023 - Elsevier
Congenital myopathies are rare and severe genetic diseases affecting the skeletal muscle
function in children and adults. They present a variable spectrum of phenotypes and a …

Lessons learned from discontinued clinical developments in Duchenne muscular dystrophy

T Markati, L De Waele, U Schara-Schmidt… - Frontiers in …, 2021 - frontiersin.org
Duchenne muscular dystrophy (DMD) is an X-linked condition caused by a deficiency of
functional dystrophin protein. Patients experience progressive muscle weakness …

Tamoxifen improves muscle structure and function of Bin1- and Dnm2-related centronuclear myopathies

C Gineste, A Simon, M Braun, D Reiss, J Laporte - Brain, 2023 - academic.oup.com
Congenital myopathies define a genetically heterogeneous group of disorders associated
with severe muscle weakness, for which no therapies are currently available. Here we …

Therapeutic strategies targeting DUX4 in FSHD

L Le Gall, E Sidlauskaite, V Mariot… - Journal of Clinical …, 2020 - mdpi.com
Facioscapulohumeral muscular dystrophy (FSHD) is a common muscle dystrophy typically
affecting patients within their second decade. Patients initially exhibit asymmetric facial and …

[HTML][HTML] Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients

L Mackels, V Mariot, L Buscemi, L Servais… - International Journal of …, 2024 - mdpi.com
Clinical trials with treatments inhibiting myostatin pathways to increase muscle mass are
currently ongoing in spinal muscular atrophy. Given evidence of potential myostatin pathway …

[HTML][HTML] Multi-omics comparisons of different forms of centronuclear myopathies and the effects of several therapeutic strategies

S Djeddi, D Reiss, A Menuet, S Freismuth… - Molecular Therapy, 2021 - cell.com
Omics analyses are powerful methods to obtain an integrated view of complex biological
processes, disease progression, or therapy efficiency. However, few studies have compared …

Diagnostic biomarkers of dilated cardiomyopathy

A Moeinafshar, N Yazdanpanah, N Rezaei - Immunobiology, 2021 - Elsevier
Background Dilated cardiomyopathy (DCM) is a condition involving dilation of cardiac
chambers, which results in contraction impairment. Besides invasive and non-invasive …

Insight into the role of myokines and myogenic regulatory factors under hypobaric hypoxia induced skeletal muscle loss

S Srivastava, R Rathor, SN Singh, G Suryakumar - Biomarkers, 2022 - Taylor & Francis
Background The present study aimed to analyse the role of myokines and the regeneration
capacity of skeletal muscle during chronic hypobaric hypoxia (CHH). Methods Male Sprague …